Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab induction therapy in biologic-experienced moderate-to-severe ulcerative colitis
2017-004230-28Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Spesolimab with Placebo (2 arms). Primary endpoint: Clinical remission at week 12. Started Jan 2018; status: completed.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-004230-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004230-28.